The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of R...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-11-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3215 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687877331451904 |
|---|---|
| author | E. L. Nasonov E. Feist |
| author_facet | E. L. Nasonov E. Feist |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other IMRDs, the role of interleukin (IL) 6 is of special interest. The introduction of mAbs tocilizumab (TCZ) and later sarilumab (SAR), both blocking the receptor of this cytokine, into clinical practice was an important achievement in the treatment of IIRDs at the beginning of the 21st century. As a novel approach in the treatment of RA, the humanized mAb against IL-6 olokizumab (OKZ) is in development by the Russian company R-PHARM under the license agreement with UCB Pharma. The review examines new data on efficacy and safety of OKZ in RA and the prospects of its use in rheumatology |
| format | Article |
| id | doaj-art-9b40ae1082db4e95bb2971f35a9aab9e |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2022-11-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-9b40ae1082db4e95bb2971f35a9aab9e2025-08-20T03:22:12ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-11-0160550551810.47360/1995-4484-2022-505-5182838The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)E. L. Nasonov0E. Feist1V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)Department of Rheumatology, Helios Clinic VogelsangGommern, cooperation partner of the Otto-vonGuericke University MagdeburgRheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation. Among the cytokines involved in the pathogenesis of RA and certain other IMRDs, the role of interleukin (IL) 6 is of special interest. The introduction of mAbs tocilizumab (TCZ) and later sarilumab (SAR), both blocking the receptor of this cytokine, into clinical practice was an important achievement in the treatment of IIRDs at the beginning of the 21st century. As a novel approach in the treatment of RA, the humanized mAb against IL-6 olokizumab (OKZ) is in development by the Russian company R-PHARM under the license agreement with UCB Pharma. The review examines new data on efficacy and safety of OKZ in RA and the prospects of its use in rheumatologyhttps://rsp.mediar-press.net/rsp/article/view/3215rheumatoid arthritisbiological agentsinterleukin-6interleukin-6 inhibitorstocilizumabolokizumab |
| spellingShingle | E. L. Nasonov E. Feist The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) Научно-практическая ревматология rheumatoid arthritis biological agents interleukin-6 interleukin-6 inhibitors tocilizumab olokizumab |
| title | The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) |
| title_full | The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) |
| title_fullStr | The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) |
| title_full_unstemmed | The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) |
| title_short | The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) |
| title_sort | prospects of interleukin 6 inhibition in rheumatoid arthritis olokizumab novel monoclonal antibodies to il 6 |
| topic | rheumatoid arthritis biological agents interleukin-6 interleukin-6 inhibitors tocilizumab olokizumab |
| url | https://rsp.mediar-press.net/rsp/article/view/3215 |
| work_keys_str_mv | AT elnasonov theprospectsofinterleukin6inhibitioninrheumatoidarthritisolokizumabnovelmonoclonalantibodiestoil6 AT efeist theprospectsofinterleukin6inhibitioninrheumatoidarthritisolokizumabnovelmonoclonalantibodiestoil6 AT elnasonov prospectsofinterleukin6inhibitioninrheumatoidarthritisolokizumabnovelmonoclonalantibodiestoil6 AT efeist prospectsofinterleukin6inhibitioninrheumatoidarthritisolokizumabnovelmonoclonalantibodiestoil6 |